Sanofi/Regeneron win a new trial on Praluent patents; BridgeBio bankrolls $30M biotech startup

→  After coming perilously close to seeing their PCSK9 drug Praluent jerked off the market, Sanofi and Regeneron have won a new trial in the case involving a rival drug at Amgen. An appeals court is giving their attorneys a green light to raise issues regarding the validity of the patents.

→ BridgeBio is bankrolling a biotech startup to the tune of $30 million. Partnering with MD Anderson, the startup — dubbed Navire Pharma — will fund work on inhibiting SHP2 in fighting cancer tumors. Shafique Virani, a business development exec at Roche/Genentech, has been named the new CEO. “Navire’s compounds potently bind SHP2 and prevent activation of the protein, blocking its ability to promote tumor growth,” said Virani.

→ The New York Times covers the federal government’s efforts at preventing shortages of the drugs and devices manufactured in Puerto Rico at scores of facilities on the badly damaged island.

→ Biogen is offering new data demonstrating that earlier initiation of treatment with Spinraza (nusinersen) may improve motor function outcomes in infants and children with spinal muscular atrophy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 48,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->